These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10473878)

  • 1. The evolution of oral antiplatelet therapy.
    Timmis SB; O'Neill WW
    Semin Interv Cardiol; 1999 Jun; 4(2):89-95. PubMed ID: 10473878
    [No Abstract]   [Full Text] [Related]  

  • 2. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
    Maree A; Fitzgerald D
    Haematologica; 2001 Nov; 86(11 Suppl 2):45-8. PubMed ID: 11926777
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena?
    Jackson G
    Int J Clin Pract; 2001; 55(6):351-2. PubMed ID: 11501219
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of the use of IIb/IIIa receptor blockers with or without the use of other anticoagulants.
    Ferguson JJ; Lau TK
    Semin Interv Cardiol; 1999 Jun; 4(2):97-102. PubMed ID: 10473879
    [No Abstract]   [Full Text] [Related]  

  • 5. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
    Tricoci P; Peterson ED
    J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical studies on glycoprotein IIb/IIIa receptor antagonist].
    Rasmussen LH; Husted SE; Clemmensen PM; Gøtzsche CO; Helqvist S; Kristensen SD; Pedersen KE; Rasmussen K; Rasmussen S
    Ugeskr Laeger; 2000 Oct; 162(44):5944-7. PubMed ID: 11094564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
    Rajagopal V; Bhatt DL
    Semin Thromb Hemost; 2004 Dec; 30(6):649-55. PubMed ID: 15630671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.
    Leebeek FW; Boersma E; Cannon CP; van de Werf FJ; Simoons ML
    Eur Heart J; 2002 Mar; 23(6):444-57. PubMed ID: 11863347
    [No Abstract]   [Full Text] [Related]  

  • 9. A cold start for oral glycoprotein IIb/IIIa antagonists.
    Curtin R; Fitzgerald DJ
    Eur Heart J; 2000 Dec; 21(24):1992-4. PubMed ID: 11102247
    [No Abstract]   [Full Text] [Related]  

  • 10. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glycoprotein IIB/IIIA receptor blockers as treatment of acute coronary syndromes and interventional cardiology].
    Abramovitch N; Halon DA; Flugelman Y; Lewis BS
    Harefuah; 1998 Jul; 135(1-2):41-7. PubMed ID: 10909532
    [No Abstract]   [Full Text] [Related]  

  • 12. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ; Guzman LA; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and economic efficiency of platelet IIb/IIIa receptor blockers in acute coronary syndromes without ST-segment elevation].
    Latour-Pérez J
    Rev Esp Cardiol; 2000 Aug; 53(8):1148-50. PubMed ID: 11032540
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
    Vorchheimer DA; Fuster V
    Circulation; 1998 Feb; 97(4):312-4. PubMed ID: 9468202
    [No Abstract]   [Full Text] [Related]  

  • 15. Contemporary view of the acute coronary syndromes.
    Moustapha A; Anderson HV
    J Invasive Cardiol; 2003 Feb; 15(2):71-9. PubMed ID: 12556619
    [No Abstract]   [Full Text] [Related]  

  • 16. [Glycoprotein 2b3a inhibitors for acute coronary syndromes: what the trials tell us].
    Elian D; Guetta V
    Harefuah; 2003 May; 142(5):350-4, 398. PubMed ID: 12803058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
    Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
    Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
    [No Abstract]   [Full Text] [Related]  

  • 18. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Dimens Crit Care Nurs; 2000; 19(3):14-9. PubMed ID: 11998001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reflections on GPIIb/IIIA inhibitors ... and all around ...].
    Neri Serneri GG
    G Ital Cardiol; 1999 Apr; 29(4):467-71. PubMed ID: 10327329
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.